In:
The Journal of Immunology, The American Association of Immunologists, Vol. 178, No. 1_Supplement ( 2007-04-01), p. S243-S243
Abstract:
Experimental allergic encephalomyelitis (EAE) is a mouse model for human multiple sclerosis (MS). While effective treatments of EAE have been developed, adapting these for use in human MS has proven difficult and therefore investigations into this model continue. Here, we examine the effects of MHC polymorphism on the control of tolerance. Our previous studies have shown that treatment of EAE with immunoglobulins (Ig) containing proteolipid protein (PLP) or myelin oligodendrocyte glycoprotein (MOG) epitopes reverses ongoing disease in both SJL/J and C57Bl/6 mice. We used F1(SJL/J x Bl/6) mice to test Ig-PLP and Ig-MOG for reversal of compatible as well as “in trans” EAE wherein disease induced by MOG epitope is treated with Ig-PLP and EAE induced by PLP epitope is treated with Ig-MOG. The findings indicated that EAE induced in F1 mice by PLP is successfully treated with Ig-PLP or Ig-MOG. However, an asymmetrical effect was observed for the treatment of MOG EAE whereby Ig-MOG reverses MOG EAE while Ig-PLP exacerbated MOG induced EAE. The mechanism underlying disease exacerbation correlated with a cytokine-induced Ig class switch among anti-MOG antibodies during treatment with Ig-PLP. Research supported by grant NS37406 from NIH.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.178.Supp.131.29
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2007
detail.hit.zdb_id:
1475085-5